Value-Based HIV FormulariesOptimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
AMCP Partnership Forum: enabling the exchange of clinical and economic information pre-FDA approval.
Academy of Managed Care Pharmacy. J Manag Care Pharm. 2017;23(1):105-112.
CMS to test enhanced medication therapy management model: aims for greater use of pharmacists, cost savings, and better outcomes.
Barlas S. P T. 2016;41(7):423-441.
Brennan-Ing M, et al. PLoS One. 2016;11(2):e0148865.
Assessment of the level of satisfaction and unmet data needs for specialty drug formulary decisions in the United States.
Choi Y, Navarro RP. J Manag Care Spec Pharm. 2016;22(4):368-375
Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results.
Eron J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAX0205LB.
Fleishman JA, et al. J Acquir Immune Defic Syndr. 2016;72(4):408-415.
A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48.
Gallant J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0105LB.
What are the incentives for Medicare prescription drug plans to consider long-term outcomes and cost?
Hung A, Perfetto EM. J Manag Care Spec Pharm. 2016;22(7):773-778.
A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.
Kuchinad KE, et al. BMC Res Notes. 2016;9:229.
Lllibre JM, et al. 24th Conference on Retroviruses and Opportunistic Infections; February 13−16, 2017; Seattle, WA. Abstract 44LB.
Malone DC. J Manag Care Pharm. 2005;11(suppl 4):S7-S10.
Demographic, insurance, and health characteristics of newly enrolled HIV-positive patients after implementation of the Affordable Care Act in California.
Satre DD, et al. Am J Public Health. 2016;106(7):1211-1213.
Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study.
Sued O, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0106LB.
Sutton SS, et al. Am J Manag Care. 2016;22(4):242-248.
Vogenberg FR, et al. P T. 2017;42(1):28-32.
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science